Results 61 to 70 of about 32,790 (255)
Advanced Science, EarlyView.A multifunctional nanoagonist (cDZ@IP) enables nano‐metabolite–driven multimodal activation of the STING pathway and enhanced immune recognition, achieving potent antitumor immunity and suppressing tumor growth and metastasis. This strategy highlights the rational design of therapeutic metabolites and establishes a new paradigm bridging nanomedicine ...
Kepeng Hu +17 more
wiley +1 more source
Structures of representative HDAC and topoisomerase I inhibitors.
, 2018 Structures of representative HDAC and topoisomerase I inhibitors.
Raffaella Cincinelli (192154) +12 more
core +1 more source
Mechanically Triggered DNA Nanovehicles for Targeted Dual‐Drug Cancer Therapy
Advanced Science, EarlyView.A mechanically triggered DNA nanovehicle is introduced that co‐releases two anticancer drugs in response to integrin‐mediated cellular forces. Cholesterol‐anchored DNA assemblies undergo force‐induced unfolding at cell–cell junctions, enabling selective, localized dual‐drug activation in cancer cells while minimizing off‐target toxicity in low‐tension ...
Murali Mohana Rao Singuru +2 more
wiley +1 more source
Frontiers in Oncology, 2019 Human castration-resistant prostate cancer (CRPC) is a significant target of clinical research. The use of DNA-damaging agents has a long history in cancer chemotherapy but is limited by their toxicities.
Jo-Fan Chang +10 more
doaj +1 more source
, 2023 DNA topoisomerases are important enzymes that stabilize DNA supercoiling and resolve entanglements. There are two main types of topoisomerases in all cells: type I, which causes single-stranded DNA breaks, and type II, which cuts double-stranded DNA ...
Nam Deuk Kim +2 more
core +1 more source
Advanced Science, EarlyView.Dual priming with minocycline and photodynamic priming reprograms the pancreatic tumor microenvironment to overcome chemoresistance. By suppressing DNA repair enzyme Tdp1, inducing photooxidative damage, and enhancing irinotecan delivery via light‐activated nanoencapsulation, this strategy remodels the tumor microenvironment and drives immune ...
Fernanda V. Cabral +7 more
wiley +1 more source
DNA-Binding Anticancer Drugs: One Target, Two Actions
Molecules, 2021 Amsacrine, an anticancer drug first synthesised in 1970 by Professor Cain and colleagues, showed excellent preclinical activity and underwent clinical trial in 1978 under the auspices of the US National Cancer Institute, showing activity against acute ...
Bruce C. Baguley +3 more
doaj +1 more source
FOS3D: A Fluorescence‐Enabled Toolkit for Characterizing a Three‐dimensional Osteosarcoma Model
Advanced Science, EarlyView.FOS3D describes fluorescent (F) osteosarcoma (OS) cells in a tri‐dimensional (3D) model. The study comprises three phases: development, where biofabrication parameters are tuned to achieve cytocompatibility and tumor‐specific mechanical properties in cell‐laden gelatin methacryloyl constructs; validation, where whole‐well fluorescence reading is ...
William Humble +9 more
wiley +1 more source
Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. [PDF]
PLoS ONE, 2009 BACKGROUND:Natural product structures have high chemical diversity and are attractive as lead structures for discovery of new drugs. One of the disease areas where natural products are most frequently used as therapeutics is oncology. METHOD AND FINDINGS:
Walid Fayad +5 more
doaj +1 more source
, 2012 Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA ...
Babich, J.W. +15 more
core +1 more source